Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study.
M L LoprestiJ J BianB J SakrR S StrengerR D LegareM FentonS M WitherbyD S DizonS V PandyaA R StuckeyD A EdmondsonJennifer GassC M EmmickT A GravesM CutitarAdam J OlszewskiWilliam M SikovPublished in: Breast cancer research and treatment (2021)
ClinicalTrials.gov identifier: NCT02789657.